Subpart B. Subpart B—Procedures for Determining the Bioavailability or Bioequivalence of Drug Products

• § 320.21 - Requirements for submission of bioavailability and bioequivalence data.
• § 320.22 - Criteria for waiver of evidence of in vivo bioavailability or bioequivalence.
• § 320.23 - Basis for measuring in vivo bioavailability or demonstrating bioequivalence.
• § 320.24 - Types of evidence to measure bioavailability or establish bioequivalence.
• § 320.25 - Guidelines for the conduct of an in vivo bioavailability study.
• § 320.26 - Guidelines on the design of a single-dose in vivo bioavailability or bioequivalence study.
• § 320.27 - Guidelines on the design of a multiple-dose in vivo bioavailability study.
• § 320.28 - Correlation of bioavailability with an acute pharmacological effect or clinical evidence.
• § 320.29 - Analytical methods for an in vivo bioavailability or bioequivalence study.
• § 320.30 - Inquiries regarding bioavailability and bioequivalence requirements and review of protocols by the Food and Drug Administration.
• § 320.31 - Applicability of requirements regarding an “Investigational New Drug Application.”
• § 320.32 - Procedures for establishing or amending a bioequivalence requirement.
• § 320.33 - Criteria and evidence to assess actual or potential bioequivalence problems.
• § 320.34 - Requirements for batch testing and certification by the Food and Drug Administration.
• § 320.35 - Requirements for in vitro testing of each batch.
• § 320.36 - Requirements for maintenance of records of bioequivalence testing.
• § 320.38 - Retention of bioavailability samples.
• § 320.63 - Retention of bioequivalence samples.